Results 141 to 150 of about 5,508,271 (271)
Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10603-10614, November 2026.ABSTRACT Aims This study aimed to perform an exploratory characterisation of metabolic phenotypes in primary care patients with type 2 diabetes mellitus (T2DM), using a predefined approach and examine their association with vitamin D status. Materials and Methods This cross‐sectional study included 178 participants randomly selected in Sergipe, Brazil.
Liliane Viana Pires +10 more
wiley +1 more source
Severe polycystic liver disease in a cat. [PDF]
JFMS Open Rep, 2023 King EM +5 more
europepmc +1 more source
Journal of Internal Medicine, Volume 300, Issue 5, Page 590-609, November 2026.Abstract Polyendocrine metabolic ovarian syndrome (PMOS), previously known as polycystic ovary syndrome, affects 10%–13% of women of reproductive age and remains underdiagnosed despite its substantial health burden. The introduction of the new PMOS nomenclature in 2026 reflects a fundamental shift in understanding the condition as a lifelong endocrine ...
Maria Forslund +5 more
wiley +1 more source
Polycystic Disease of Liver [PDF]
Proceedings of the Royal Society of Medicine, 1939 openaire +2 more sources
Low Weight Loss Response to Incretin Analogs: A Systematic Review
Obesity Reviews, Volume 27, Issue 11, November 2026.ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley +1 more source
Liver transplantation for polycystic liver disease: a case report. [PDF]
J Surg Case Rep, 2023 Niibek M, Uksov A.
europepmc +1 more source
GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms
Obesity Reviews, Volume 27, Issue 11, November 2026.ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani +8 more
wiley +1 more source
The FASEB Journal, Volume 40, Issue 19, 15 October 2026.Schematic illustrating that NR4A1‐driven granulosa cell ferroptosis mediates obesity‐related ovarian dysfunction, while metformin‐mediated ovarian protection is achieved via suppression of the PI3K/AKT–NR4A1 ferroptotic signaling cascade. ABSTRACT Obesity triggers ovarian dysfunction and female infertility accompanied by granulosa cell damage ...
Huihui Wang +17 more
wiley +1 more source
Congenital Polycystic Disease of the Liver and Kidneys [PDF]
BMJ, 1946 A P, Waterson, P R, Morgan
openaire +3 more sources
Streamlining Diagnosis of Bardet–Biedl Syndrome: New Diagnostic Algorithm With Updated Criteria
American Journal of Medical Genetics Part A, Volume 200, Issue 10, Page 2181-2198, October 2026.ABSTRACT Considerable advances have been made in our understanding of Bardet–Biedl syndrome (BBS), particularly in its core clinical features and molecular genetics, warranting an update to the existing diagnostic criteria framework. Using a rigorous, evidence‐based, and consensus‐driven process, a multidisciplinary group of international experts and ...
Jeremy J. Pomeroy +16 more
wiley +1 more source